Our Pricing

Wegovy Click Chart UK: Evidence-Based Weight Loss Results

The wegovy click chart uk results provide transparent clinical data from the STEP trial programme, demonstrating how semaglutide 2.4mg achieves significant weight reduction in adults with obesity. At Cured Pharmacy, we help UK patients understand these evidence-based outcomes before starting treatment from £79.00, with full prescriber assessment and discreet delivery included.

Understanding the Wegovy Click Chart UK Data

The Wegovy click chart presents weight loss trajectories from the landmark STEP clinical trial programme, which enrolled over 4,500 participants across multiple international sites including the UK [1]. This visual tool maps the gradual dose escalation protocol—starting at 0.25mg weekly and increasing to the maintenance dose of 2.4mg over 16-20 weeks—alongside corresponding weight reduction percentages.

In the STEP 1 trial, participants receiving Wegovy 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. Importantly, 86.4% of Wegovy-treated patients achieved at least 5% weight loss, whilst 69.1% reached 10% or greater reduction—thresholds associated with meaningful improvements in cardiovascular and metabolic health markers [1].

The click chart illustrates that weight loss accelerates during the dose escalation phase, with the steepest decline occurring between weeks 20 and 40, before plateauing as patients reach their individual response threshold [2]. This pattern helps UK prescribers set realistic expectations and identify patients who may benefit from extended treatment duration.

Wegovy Dosing Schedule and Weight Loss Timeline

Wegovy's graduated dosing protocol is central to its safety profile and efficacy. The MHRA-approved escalation schedule begins with 0.25mg once weekly for four weeks, doubling to 0.5mg for the next four weeks, then progressing through 1mg, 1.7mg, and finally reaching the 2.4mg maintenance dose by week 17 [2].

This incremental approach minimises gastrointestinal side effects—the most common tolerability concern—by allowing the body to adapt to semaglutide's effects on gastric emptying and appetite regulation [2]. Clinical data shows that patients who follow the prescribed escalation schedule have significantly lower discontinuation rates compared to those attempting faster dose increases.

Most UK patients begin noticing appetite suppression within the first two weeks, with measurable weight loss typically evident by week 4-6. Peak weight reduction generally occurs between months 9 and 15, after which weight stabilises if dietary and activity modifications are maintained alongside medication [1][2].

What to Expect During Each Dosing Phase

During the initial 0.25mg and 0.5mg phases, patients often report reduced food cravings and earlier satiety, though weight loss remains modest—typically 2-4% of baseline body weight. The therapeutic doses of 1.7mg and 2.4mg produce more pronounced effects, with patients frequently describing a fundamental shift in their relationship with food rather than simple appetite suppression. Your UK prescriber at Cured Pharmacy will monitor your progress at each stage, adjusting the timeline if tolerability concerns arise.

Wegovy Click Chart UK Results Compared to Other Weight Loss Treatments

When evaluating the wegovy click chart uk results against alternative GLP-1 receptor agonists, semaglutide 2.4mg demonstrates superior weight reduction compared to earlier-generation treatments. The STEP 2 trial directly compared Wegovy to liraglutide 3mg (marketed as Saxenda), showing 9.6% average weight loss with semaglutide versus 3.4% with liraglutide over 68 weeks [3].

However, newer dual GIP/GLP-1 receptor agonists have shown even greater efficacy in head-to-head trials. Tirzepatide 15mg produced average weight reductions of 22.5% in the SURMOUNT-1 trial—substantially higher than semaglutide's outcomes, though both medications require similar injection frequency and dietary adherence [4].

For UK patients, the choice between treatments depends on individual medical history, tolerability profile, cost considerations, and prescriber assessment. Wegovy remains the most extensively studied weight loss medication in the UK market, with robust long-term safety data and established cardiovascular benefit profiles that inform prescribing decisions [1][3].

Injectable vs Oral Weight Loss Medications

Whilst injectable semaglutide shows superior weight loss outcomes in clinical trials, oral alternatives like orlistat and naltrexone-bupropion combinations remain available for patients who prefer tablet-based treatments. Orlistat produces average weight reductions of 3-5% when combined with calorie restriction, whilst Mysimba achieves approximately 5-9% reduction in responders—both considerably lower than Wegovy's clinical trial results [3]. Your UK prescriber will discuss whether injectable or oral treatment aligns better with your lifestyle and treatment goals.

Real-World Wegovy Results in UK Clinical Practice

Whilst the Wegovy click chart derives from controlled clinical trial environments, real-world evidence from UK prescribing data suggests slightly lower average weight loss—typically 10-12% over 12 months—reflecting the challenges of medication adherence, dietary consistency, and diverse patient populations outside trial protocols [5].

NHS pilot programmes evaluating Wegovy in primary care settings have documented that approximately 15-20% of patients discontinue treatment within the first six months, primarily due to gastrointestinal side effects or inadequate weight loss response [5]. These figures underscore the importance of comprehensive patient selection, ongoing clinical monitoring, and realistic expectation-setting during the initial consultation.

At Cured Pharmacy, our UK-registered clinical team conducts thorough assessments to identify patients most likely to benefit from semaglutide therapy, considering factors including BMI, weight-related comorbidities, previous weight loss attempts, and contraindications. Superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures all prescribing decisions align with current MHRA guidance and NICE recommendations for obesity management.

Maximising Wegovy Weight Loss Results: Evidence-Based Strategies

Clinical trial data consistently demonstrates that patients who combine Wegovy with structured lifestyle interventions achieve superior outcomes compared to medication alone. The STEP 1 trial protocol included a 500-calorie daily deficit and 150 minutes of weekly physical activity—modifications that amplified semaglutide's pharmacological effects [1].

Protein intake optimisation appears particularly important during weight loss phases, with studies suggesting 1.2-1.6g per kilogram of body weight helps preserve lean muscle mass whilst predominantly reducing fat tissue [6]. Adequate hydration and fibre consumption also mitigate common gastrointestinal side effects, improving treatment adherence and comfort.

UK patients should also consider the timing of dose administration and meal patterns. Injecting Wegovy on the same day each week—regardless of meal timing—maintains stable plasma concentrations, whilst eating smaller, more frequent meals often proves better tolerated than traditional three-meal patterns during the initial dose escalation phases [2][6].

Monitoring Progress Beyond the Scale

Whilst the Wegovy click chart focuses on percentage body weight reduction, UK prescribers increasingly emphasise non-scale victories including waist circumference reduction, improved HbA1c levels in patients with type 2 diabetes, blood pressure normalisation, and enhanced mobility. These cardiometabolic improvements often manifest before significant scale changes become apparent, particularly in patients with substantial muscle mass or fluid retention. Your clinical team at Cured Pharmacy can guide you on comprehensive progress tracking that extends beyond simple weight measurements.

Starting Wegovy Treatment at Cured Pharmacy

Beginning Wegovy treatment requires a clinical assessment by a UK-registered prescriber to confirm suitability, review contraindications, and establish baseline measurements. At Cured Pharmacy, this consultation process takes under three minutes online and includes evaluation of your BMI, weight-related health conditions, current medications, and previous weight management attempts.

Once approved, your first Wegovy prescription starts at £79.00 for the initial dosing pack, with all pricing displayed transparently before consultation—no hidden fees or subscription traps. We dispense only genuine UK-licensed Wegovy pens manufactured by Novo Nordisk, delivered in 100% discreet packaging within 2-4 working days to any UK address.

Our clinical team provides ongoing support throughout your treatment journey, including guidance on managing side effects, optimising injection technique, and determining appropriate treatment duration. As a fully registered UK pharmacy (GPhC 9012511), we maintain the highest standards of pharmaceutical care whilst offering the convenience and competitive pricing of online service.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
3. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
4. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
5. Mahase, E. (2023). Weight loss drugs: UK real world data show high discontinuation rates. BMJ, 381, p1116. https://doi.org/10.1136/bmj.p1116
6. Ryan, D. H., & Yockey, S. R. (2017). Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Current Obesity Reports, 6(2), 187–194. https://doi.org/10.1007/s13679-017-0262-y

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including adherence, lifestyle modifications, and baseline health status.